Venn Life Sciences Holdings Stock London S.E.
Equities
GB00B9275X97
Biotechnology & Medical Research
Sales 2023 | 56.04M 70.17M | Sales 2024 * | 62.07M 77.71M | Capitalization | 194M 243M |
---|---|---|---|---|---|
Net income 2023 | 16M 20.03M | Net income 2024 * | 9M 11.27M | EV / Sales 2023 | 2.88 x |
Net cash position 2023 * | 34.79M 43.56M | Net cash position 2024 * | 41.48M 51.94M | EV / Sales 2024 * | 2.46 x |
P/E ratio 2023 |
10.1
x | P/E ratio 2024 * |
22.5
x | Employees | - |
Yield 2023 * |
1.42% | Yield 2024 * |
0.82% | Free-Float | 60.8% |
Latest transcript on Venn Life Sciences Holdings
Managers | Title | Age | Since |
---|---|---|---|
Yamin Khan
CEO | Chief Executive Officer | 55 | 21-10-12 |
Ian O'Connell
FOU | Founder | 37 | 11-01-31 |
Cathal Friel
FOU | Founder | 59 | 11-01-31 |
Members of the board | Title | Age | Since |
---|---|---|---|
Director/Board Member | 57 | 22-06-07 | |
Cathal Friel
FOU | Founder | 59 | 11-01-31 |
Brendan Buckley
FOU | Founder | 73 | 18-11-30 |
1st Jan change | Capi. | |
---|---|---|
+4.09% | 43.84B | |
+46.73% | 41.25B | |
+9.45% | 41.68B | |
-10.92% | 27.04B | |
+9.32% | 25.53B | |
-24.87% | 18.18B | |
+29.70% | 12.29B | |
+1.28% | 12.29B | |
+7.78% | 11.15B |